🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Elias Chandran

National Institutes of Health

ORCID: 0000-0002-0150-7765

Also affiliated with National Cancer Institute, Center for Cancer Research

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 14 papers. Top paper: “A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (laser)—design and rationale”.

A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (laser)—design and rationale

Future Oncology(2025)10.1080/14796694.2025.2480534
N/A
0.165DataRank · unranked
2 citations

Elias Chandran, Saad Atiq, Andre R. Kydd, Daniel M. Girardi, Lisa Ley +14 more

Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials

Cancer Treatment Reviews(2023)10.1016/j.ctrv.2023.102623
N/A
0DataRank · unranked
37 citations

Elias Chandran, Charalampos S. Floudas, Hyoyoung Choo‐Wosoba, Gisela Butera, Mario Roselli +3 more

Emerging treatment options for prostate cancer

Expert Review of Anticancer Therapy(2023)10.1080/14737140.2023.2208352
N/A
0DataRank · unranked
19 citations

Elias Chandran, Fatima Karzai, Ravi A. Madan, Jeanny B. Aragon‐Ching, Mohammad Atiq

A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4607
N/A
0DataRank · unranked
3 citations

Nicholas I. Simon, Scot A. Niglio, Lisa Ley, Lisa M. Cordes, Rouf Banday +15 more

A phase I study of bintrafusp alfa and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic genitourinary (GU) malignancies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4571
N/A
0DataRank · unranked
1 citations

Scot A. Niglio, Elias Chandran, Giovanni Maria Iannantuono, Salah Boudjadi, Rouf Banday +15 more

Effects of docetaxel on circulating immune cell subsets and association with outcomes in metastatic castration-sensitive prostate cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.207
N/A
0DataRank · unranked
0 citations

Meghali Goswami, Renee N. Donahue, Mohammad Atiq, Fatima Karzai, Marijo Bilušić +13 more

Final results from a phase 1 trial and expansion cohorts of cabozantinib and nivolumab alone or with ipilimumab for advanced/metastatic genitourinary tumors

Research Square(2023)10.21203/rs.3.rs-2924051/v1
N/A
0DataRank · unranked
0 citations

Scot A. Niglio, Rosa Nadal, Andre R. Kydd, Nicholas I. Simon, Lisa Ley +36 more

FDG PET/CT and NaF PET/CT imaging quantification of osseous metastatic lesions in patients with metastatic genitourinary (mGU) cancer and their association with survival outcomes.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e16573
N/A
0DataRank · unranked
0 citations

Nicholas I. Simon, Elias Chandran, Katherine Lei, Nicholas Peter Verdini, Jeffrey Lin +15 more

Association of 18F-FDG PET characteristics and survival outcomes using whole body tumor analysis in patients (pts) with metastatic genitourinary (GU) malignancies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4600
N/A
0DataRank · unranked
0 citations

Rod Carlo Columbres, Elias Chandran, Scot A. Niglio, Lisa M. Cordes, Lisa Ley +9 more

Comparison of peripheral blood markers in predicting the occurrence of immune-related adverse events in patients with metastatic genitourinary cancer treated with cabozantinib + nivolumab +/- ipilimumab.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e16506
N/A
0DataRank · unranked
0 citations

Elias Chandran, Nicholas I. Simon, Lisa Ley, Lisa M. Cordes, Tzu-fang Wang +13 more

Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis

BMJ Oncology(2024)10.1136/bmjonc-2024-000335
N/A
0DataRank · unranked
20 citations

Giovanni Maria Iannantuono, Saad Atiq, Dilara Akbulut, Ninet Sinaii, Nicholas I. Simon +11 more

Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009–2023)

European Journal of Cancer(2025)10.1016/j.ejca.2025.115589
N/A
0DataRank · unranked
6 citations

Charalampos S. Floudas, Marco Filetti, Tommaso Giovagnoli, Stefano Sganga, Antonio Vitale +13 more

Lutetium-177-PSMA-617: A Vision of the Future

Cancer Biology & Therapy(2022)10.1080/15384047.2022.2037985
N/A
0DataRank · unranked
27 citations

William D. Figg, Ravi A. Madan, Elias Chandran

Antibody–drug conjugates in rare genitourinary tumors: review and perspectives

Current Opinion in Oncology(2025)10.1097/cco.0000000000001141
N/A
0DataRank · unranked
0 citations

Md Shahid Sarwar, Saad Atiq, Raju Chelluri, Sandeep Gurram, Elias Chandran +8 more